Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity by Viral Load, S Gene Variants and Demographic Factors, and the Utility of Lateral Flow Devices to Prevent Transmission
- PMID: 33972994
- PMCID: PMC8136027
- DOI: 10.1093/cid/ciab421
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity by Viral Load, S Gene Variants and Demographic Factors, and the Utility of Lateral Flow Devices to Prevent Transmission
Abstract
Background: How severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity varies with viral load is incompletely understood. Whether rapid point-of-care antigen lateral flow devices (LFDs) detect most potential transmission sources despite imperfect clinical sensitivity is unknown.
Methods: We combined SARS-CoV-2 testing and contact tracing data from England between 1 September 2020 and 28 February 2021. We used multivariable logistic regression to investigate relationships between polymerase chain reaction (PCR)-confirmed infection in contacts of community-diagnosed cases and index case viral load, S gene target failure (proxy for B.1.1.7 infection), demographics, SARS-CoV-2 incidence, social deprivation, and contact event type. We used LFD performance to simulate the proportion of cases with a PCR-positive contact expected to be detected using 1 of 4 LFDs.
Results: In total, 231 498/2 474 066 (9%) contacts of 1 064 004 index cases tested PCR-positive. PCR-positive results in contacts independently increased with higher case viral loads (lower cycle threshold [Ct] values), for example, 11.7% (95% confidence interval [CI] 11.5-12.0%) at Ct = 15 and 4.5% (95% CI 4.4-4.6%) at Ct = 30. B.1.1.7 infection increased PCR-positive results by ~50%, (eg, 1.55-fold, 95% CI 1.49-1.61, at Ct = 20). PCR-positive results were most common in household contacts (at Ct = 20.1, 8.7% [95% CI 8.6-8.9%]), followed by household visitors (7.1% [95% CI 6.8-7.3%]), contacts at events/activities (5.2% [95% CI 4.9-5.4%]), work/education (4.6% [95% CI 4.4-4.8%]), and least common after outdoor contact (2.9% [95% CI 2.3-3.8%]). Contacts of children were the least likely to test positive, particularly following contact outdoors or at work/education. The most and least sensitive LFDs would detect 89.5% (95% CI 89.4-89.6%) and 83.0% (95% CI 82.8-83.1%) of cases with PCR-positive contacts, respectively.
Conclusions: SARS-CoV-2 infectivity varies by case viral load, contact event type, and age. Those with high viral loads are the most infectious. B.1.1.7 increased transmission by ~50%. The best performing LFDs detect most infectious cases.
Keywords: B.1.1.7 variant; SARS-CoV-2; contact tracing; infectivity; lateral flow device.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Figures





Similar articles
-
Performance of antigen lateral flow devices in the UK during the alpha, delta, and omicron waves of the SARS-CoV-2 pandemic: a diagnostic and observational study.Lancet Infect Dis. 2023 Aug;23(8):922-932. doi: 10.1016/S1473-3099(23)00129-9. Epub 2023 Mar 28. Lancet Infect Dis. 2023. PMID: 37001541 Free PMC article.
-
Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study.Lancet Microbe. 2021 Sep;2(9):e461-e471. doi: 10.1016/S2666-5247(21)00143-9. Epub 2021 Jun 30. Lancet Microbe. 2021. PMID: 34226893 Free PMC article.
-
SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study.Lancet Infect Dis. 2021 Mar;21(3):333-343. doi: 10.1016/S1473-3099(20)30833-1. Epub 2020 Nov 2. Lancet Infect Dis. 2021. PMID: 33152271 Free PMC article.
-
Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.Cochrane Database Syst Rev. 2021 Mar 24;3(3):CD013705. doi: 10.1002/14651858.CD013705.pub2. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 Jul 22;7:CD013705. doi: 10.1002/14651858.CD013705.pub3. PMID: 33760236 Free PMC article. Updated.
-
Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.Cochrane Database Syst Rev. 2020 Aug 26;8(8):CD013705. doi: 10.1002/14651858.CD013705. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2021 Mar 24;3:CD013705. doi: 10.1002/14651858.CD013705.pub2. PMID: 32845525 Free PMC article. Updated.
Cited by
-
Within-host diversity improves phylogenetic and transmission reconstruction of SARS-CoV-2 outbreaks.bioRxiv [Preprint]. 2022 Jun 7:2022.06.07.495142. doi: 10.1101/2022.06.07.495142. bioRxiv. 2022. Update in: Elife. 2023 Sep 21;12:e84384. doi: 10.7554/eLife.84384. PMID: 35702156 Free PMC article. Updated. Preprint.
-
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.Lancet Infect Dis. 2021 Nov;21(11):1529-1538. doi: 10.1016/S1473-3099(21)00289-9. Epub 2021 Jun 23. Lancet Infect Dis. 2021. PMID: 34174193 Free PMC article.
-
Modelling the impact of non-pharmaceutical interventions on workplace transmission of SARS-CoV-2 in the home-delivery sector.PLoS One. 2023 May 5;18(5):e0284805. doi: 10.1371/journal.pone.0284805. eCollection 2023. PLoS One. 2023. PMID: 37146037 Free PMC article.
-
Modelling the impact of repeat asymptomatic testing policies for staff on SARS-CoV-2 transmission potential.J Theor Biol. 2023 Jan 21;557:111335. doi: 10.1016/j.jtbi.2022.111335. Epub 2022 Nov 2. J Theor Biol. 2023. PMID: 36334850 Free PMC article.
-
A nucleic acid amplification test-based strategy does not help inform return to work for healthcare workers with COVID-19.Influenza Other Respir Viruses. 2022 Sep;16(5):851-853. doi: 10.1111/irv.13000. Epub 2022 May 26. Influenza Other Respir Viruses. 2022. PMID: 35615983 Free PMC article.
References
-
- Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA 2020; 323:1545–6. - PubMed
Publication types
MeSH terms
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous